Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ritonavir

« Back to Dashboard
Ritonavir is the generic ingredient in two branded drugs marketed by Abbott, Abbvie, and Roxane, and is included in five NDAs. There are fourteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty-one drug master file entries for ritonavir. Two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: ritonavir

Drug Master File Entries: see list21
Suppliers / Packaging: see list4
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Tentative approvals for RITONAVIR

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL25MG
<disabled><disabled>TABLET; ORAL50MG

Clinical Trials for: ritonavir

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
Status: Recruiting Condition: AIDS-related Dementia Complex

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects
Status: Completed Condition: HIV Infections

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants
Status: Completed Condition: Healthy

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Status: Active, not recruiting Condition: HIV Infections

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status: Completed Condition: Acquired Immunodeficiency Syndrome

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CAPSULE;ORAL020945-001Jun 29, 1999RXYes7,432,294*PED<disabled>Y<disabled>
CAPSULE;ORAL020680-001Mar 1, 1996DISCNNo5,635,523*PED<disabled> <disabled>
CAPSULE;ORAL020945-001Jun 29, 1999RXYes6,703,403*PED<disabled>Y<disabled>
SOLUTION;ORAL020659-001Mar 1, 1996RXYes6,037,157*PED<disabled>Y<disabled>
TABLET;ORAL022417-001Feb 10, 2010RXYes6,037,157*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn